Recently, BeiGene announced that the US Food and Drug Administration (FDA) has approved the use of BeiGene (Trastuzumab) in combination with platinum and fluorouracil chemotherapy for first-line treatment of adult patients with unresectable or metastatic HER2 negative gastric or gastroesophageal junction (G/GEJ) cancer expressing PD-L1 (≥ 1).